Prime Medicine said it won an arbitration dispute against Beam Therapeutics over gene-editing technology restrictions in a 2019 agreement. An arbitrator ruled Prime’s work on a treatment for alpha-1 antitrypsin deficiency (AATD) did not violate the non-compete terms designed to prevent direct competition between the two spinouts. Prime said the ruling clears the way to start a clinical trial for AATD this quarter, and the decision lifted the company’s stock by 11% on Wednesday. The outcome is a setback for Beam, which had been positioned as a second well-capitalized gene-editing contender after originating from the same lab. A separate report also noted related market developments around post-FDA reversal efforts by Saol and emerging European regulatory review approaches, underscoring the broader regulatory uncertainty in rare-disease and gene-editing development cycles.